Financing
Bristol-Myers Squibb·Cash Flow Statement·11 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Net cash from financing activities | — | — | — | -$993.0M | -$1.8B | -$1.5B | -$6.0B | -$1.6B |
| Dividends paid | $1.2B | $1.2B | $1.2B | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B |
| Repayments of debt | $395.0M | $2.5B | $0.0 | $0.0 | $643.0M | $229.0M | $10.1B | $500.0M |
| Proceeds from other short-term debt | $326.0M | $95.0M | — | $368.0M | $58.0M | $5.0M | — | $321.0M |
| Proceeds from other short-term debt | $326.0M | $95.0M | — | $368.0M | $58.0M | $5.0M | — | $321.0M |
| Proceeds from other short-term debt | $326.0M | $95.0M | — | $368.0M | $58.0M | $5.0M | — | $321.0M |
| Proceeds from Bridge Loan | $326.0M | $95.0M | — | $368.0M | $58.0M | $5.0M | — | $321.0M |
| Proceeds from Other Short-Term Debt | $326.0M | $95.0M | — | $368.0M | $58.0M | $5.0M | — | $321.0M |
| Stock option proceeds and other, net | -$6.0M | — | -$19.0M | -$103.0M | $0.0 | -$3.0M | -$33.0M | -$98.0M |
| Proceeds from Issuance of Commercial Paper | — | — | — | $0.0 | $0.0 | $0.0 | $0.0 | — |
| Repayment of commercial paper | $2.7B | $269.0M | — | — | — | $0.0 | $0.0 | — |